All In Biotech

Drug Trial Radar · NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™)

Last checked: Nov 20, 2026Latest source record: Dec 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,602 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,602

Actual

Start

Mar 2005

Primary completion

Jun 2008

Study completion Nov 2010

Sponsor

Lead sponsor
Cardiovascular Research Foundation, New YorkAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Scientific Corporation; The Medicines Company
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strategy. 2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™ stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.

Conditions

  • Myocardial Infarction

Interventions

  • BivalirudinDrug

    Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).

  • Unfractionated heparinDrug

    60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).

  • Bare metal stentDevice

    Uncoated bare metal stent

  • Paclitaxel-eluting stentDevice

    slow rate-release paclitaxel-eluting stent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding EventsTime frame: 30 Days
  2. Stent Arm - Ischemic Target Lesion RevascularizationTime frame: 1 year
  3. Stent Arm - Death, Reinfarction, Stroke, or Stent ThrombosisTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LeBauer CV Research Foundation

    Greensboro, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.